170 related articles for article (PubMed ID: 11369637)
1. Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T-cell antigen receptor-alphabeta.
Lan F; Zeng D; Huie P; Higgins JP; Strober S
Blood; 2001 Jun; 97(11):3458-65. PubMed ID: 11369637
[TBL] [Abstract][Full Text] [Related]
2. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
3. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
[TBL] [Abstract][Full Text] [Related]
4. CD8(+), alphabeta-TCR(+), and gammadelta-TCR(+) cells in the recipient hematopoietic environment mediate resistance to engraftment of allogeneic donor bone marrow.
Xu H; Exner BG; Cramer DE; Tanner MK; Mueller YM; Ildstad ST
J Immunol; 2002 Feb; 168(4):1636-43. PubMed ID: 11823491
[TBL] [Abstract][Full Text] [Related]
5. Antigen-primed CD8+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing.
Komatsu M; Mammolenti M; Jones M; Jurecic R; Sayers TJ; Levy RB
Blood; 2003 May; 101(10):3991-9. PubMed ID: 12521999
[TBL] [Abstract][Full Text] [Related]
6. Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation.
Pillai AB; George TI; Dutt S; Teo P; Strober S
J Immunol; 2007 May; 178(10):6242-51. PubMed ID: 17475852
[TBL] [Abstract][Full Text] [Related]
7. Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis.
Jiang Z; Podack E; Levy RB
Blood; 2001 Jul; 98(2):390-7. PubMed ID: 11435308
[TBL] [Abstract][Full Text] [Related]
8. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
Marks L; Altman NH; Podack ER; Levy RB
Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
[TBL] [Abstract][Full Text] [Related]
9. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.
Ito M; Shizuru JA
Biol Blood Marrow Transplant; 1999; 5(6):357-68. PubMed ID: 10595813
[TBL] [Abstract][Full Text] [Related]
10. Donor double-negative Treg promote allogeneic mixed chimerism and tolerance.
He KM; Ma Y; Wang S; Min WP; Zhong R; Jevnikar A; Zhang ZX
Eur J Immunol; 2007 Dec; 37(12):3455-66. PubMed ID: 18000953
[TBL] [Abstract][Full Text] [Related]
11. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
12. CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients.
Blazar BR; Taylor PA; Vallera DA
Transplantation; 1997 Aug; 64(4):571-6. PubMed ID: 9293867
[TBL] [Abstract][Full Text] [Related]
13. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
14. Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation.
Pillai A; Teo P; George T; Mukhopadhyay A; Dejbakhsh-Jones S; Strober S
Bone Marrow Transplant; 2007 Sep; 40(5):487-97. PubMed ID: 17603512
[TBL] [Abstract][Full Text] [Related]
15. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
16. The role of alphabeta- and gammadelta-T cells in allogenic donor marrow on engraftment, chimerism, and graft-versus-host disease.
Huang Y; Cramer DE; Ray MB; Chilton PM; Que X; Ildstad ST
Transplantation; 2001 Dec; 72(12):1907-14. PubMed ID: 11773887
[TBL] [Abstract][Full Text] [Related]
17. Bone Marrow Graft-Versus-Host Disease in Major Histocompatibility Complex-Matched Murine Reduced-Intensity Allogeneic Hemopoietic Cell Transplantation.
Shahin K; Mattar Z; Silveira P; Hsu WH; Bendall L; Hart D; Bradstock KF
Transplantation; 2017 Nov; 101(11):2695-2704. PubMed ID: 28319565
[TBL] [Abstract][Full Text] [Related]
18. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.
Blazar BR; Lees CJ; Martin PJ; Noelle RJ; Kwon B; Murphy W; Taylor PA
J Immunol; 2000 Nov; 165(9):4901-9. PubMed ID: 11046015
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning.
Kim YM; Mapara MY; Down JD; Johnson KW; Boisgerault F; Akiyama Y; Benichou G; Pelot M; Zhao G; Sykes M
Blood; 2004 Jan; 103(2):732-9. PubMed ID: 14512313
[TBL] [Abstract][Full Text] [Related]
20. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
